|Institution:||University College London|
|Salary:||£29,089 - £34,090|
|Line 1:||University College London|
The Nathwani group at the UCL Cancer Institute focuses on developing novel therapeutic applications using gene transfer technology. The purpose of this position is to use adeno-associated viral (AAV) vectors for gene therapy of haemophilia A, a life threatening X-linked bleeding disorder as well as other monogenetic and acquired disorders.
The appointee will work on our gene therapy programme and will generate and purify AAV vectors and develop the assays required for the assessment of efficacy and safety of gene therapy. The candidate will use the vectors generated for in-vitro studies and will support the analysis of samples derived from in-vivo evaluation of the vector. The candidate will also play a crucial role in analyzing samples from the on-going gene therapy clinical trials.
This post is funded for 18 months in the first instance.